DIFFERENTIAL EFFECTS OF PEROXISOME PROLIFERATORACTIVATOR RECEPTOR (PPAR) ALPHA AND GAMMA AGONISTS ON BODY WEIGHT AND ADIPOSE DEPOTS IN FRUCTOSE FED WISTAR RATS
Journal
Journal of Morphological Sciences /JMS
Date Issued
2018
Author(s)
Abstract
The aim of this study was to investigate the effect of fenofibrate (PPARalpha agonist) and rosiglitazone (PPAR-gamma agonist) on body weight and
adipose depots in an experimental model of the metabolic syndrome.
Metabolic syndrome was induced in 48 male Wistar rats by adding a
fructose in drinking water (10% solution) for 12 weeks. During the last 4 weeks, 16
rats were treated with fenofibrate (100 mg/kg/day), 16 rats were treated with
rosiglitazone (5 mg/kg/day) by intragastric tube, while the remaining 16 did not
receive any medication (fructose group). Another control group of 16 rats consumed
standard rat chow and water for 12 weeks.
Chronic fructose administration for 12 weeks significantly increased the
body weight (p<0.05), as well as the weight of the measured fat pads: perirenal
(p<0.001) and epididymal (p<0.001) as representatives of the visceral adipose
depots and the inguinal pads (p<0.05) as a representative of the subcutaneous
adipose depots compared to the control group. This was accompanied with a
decrease of the subcutaneous/visceral fat ratio. Treatment with fenofibrate over the
final 4 weeks significantly decreased the body weight (p<0.001) and the weight of
the epididymal, perirenal and inguinal fat pads (p<0.001 for all parameters), without
changes of the subcutaneous/visceral fat ratio.
On the other hand, rosiglitazone promoted weight gain. Treatment with this
PPAR-gamma agonist significantly decreased the weight of the epididymal
(p<0.01) and perirenal (p<0.05) pads, but increased the weight of the inguinal fat
pads (p<0.001) compared to the fructose group, which led to an increase of the
subcutaneous/visceral fat ratio.
This study indicates that treatment with the PPAR-alpha agonist fenofibrate
decreases body weight and reduces the fat depots, whereas PPAR-gamma agonist
promotes weight gain and a body fat redistribution from visceral towards
subcutaneous depots in an animal nutritive model of the metabolic syndrome
adipose depots in an experimental model of the metabolic syndrome.
Metabolic syndrome was induced in 48 male Wistar rats by adding a
fructose in drinking water (10% solution) for 12 weeks. During the last 4 weeks, 16
rats were treated with fenofibrate (100 mg/kg/day), 16 rats were treated with
rosiglitazone (5 mg/kg/day) by intragastric tube, while the remaining 16 did not
receive any medication (fructose group). Another control group of 16 rats consumed
standard rat chow and water for 12 weeks.
Chronic fructose administration for 12 weeks significantly increased the
body weight (p<0.05), as well as the weight of the measured fat pads: perirenal
(p<0.001) and epididymal (p<0.001) as representatives of the visceral adipose
depots and the inguinal pads (p<0.05) as a representative of the subcutaneous
adipose depots compared to the control group. This was accompanied with a
decrease of the subcutaneous/visceral fat ratio. Treatment with fenofibrate over the
final 4 weeks significantly decreased the body weight (p<0.001) and the weight of
the epididymal, perirenal and inguinal fat pads (p<0.001 for all parameters), without
changes of the subcutaneous/visceral fat ratio.
On the other hand, rosiglitazone promoted weight gain. Treatment with this
PPAR-gamma agonist significantly decreased the weight of the epididymal
(p<0.01) and perirenal (p<0.05) pads, but increased the weight of the inguinal fat
pads (p<0.001) compared to the fructose group, which led to an increase of the
subcutaneous/visceral fat ratio.
This study indicates that treatment with the PPAR-alpha agonist fenofibrate
decreases body weight and reduces the fat depots, whereas PPAR-gamma agonist
promotes weight gain and a body fat redistribution from visceral towards
subcutaneous depots in an animal nutritive model of the metabolic syndrome
File(s)![Thumbnail Image]()
Loading...
Name
document.pdf
Size
941.38 KB
Format
Adobe PDF
Checksum
(MD5):7400e841951c1181d04ef438e266e783